How does Amplia’s ACCENT trial compare to MPACT and POLO in pancreatic cancer response rates?

How do Amplia’s ACCENT trial results stack up against benchmark pancreatic cancer studies?

Amplia Therapeutics Limited (ASX: ATX) has started to draw attention from both oncology researchers and investors after its latest ACCENT trial update confirmed a 31% objective response rate (ORR) in patients with advanced pancreatic cancer treated with its lead drug candidate, narmafotinib. The Australian biotech is developing narmafotinib, a best-in-class FAK (focal adhesion kinase) inhibitor, as a chemotherapy adjunct. Its early results are outperforming historical standards established by major pancreatic cancer studies, including the pivotal MPACT trial and, to some extent, the targeted POLO trial.

The MPACT trial, which helped establish Abraxane plus gemcitabine as a global first-line standard of care, demonstrated a 23% ORR in metastatic pancreatic cancer. Amplia Therapeutics’ ACCENT data, recorded across 55 patients, has already exceeded this benchmark despite being in early-stage development. The latest confirmed partial response—sustained tumor shrinkage of more than 30% with no new lesions—brings the total to 17, representing a meaningful efficacy signal in a notoriously aggressive cancer type.

The POLO trial, by contrast, tested the PARP inhibitor olaparib in a subset of BRCA-mutated pancreatic cancer patients and achieved its approval based primarily on progression-free survival benefits rather than high response rates. Narmafotinib’s broader applicability in an unselected patient population could position it differently, offering clinical benefit to a wider group of patients if survival outcomes ultimately align with its current response advantage.

Why are investors and clinicians closely watching Amplia’s response rates compared to MPACT and POLO?

Analysts and clinical observers consider early response rates an important leading indicator of future regulatory success, particularly when they exceed well-documented benchmarks by more than five percentage points. Amplia Therapeutics’ 31% ORR, surpassing MPACT by eight percentage points, is significant because pancreatic cancer historically has very limited incremental gains from new agents. Early efficacy differentials of this magnitude often influence whether regulators consider a drug for expedited pathways such as FDA fast-track or breakthrough therapy designations.

The design of the ACCENT trial also plays a role in how these results are interpreted. Conducted across seven Australian and five South Korean sites, the trial uses a combination of gemcitabine and Abraxane, which allows direct comparison to MPACT. Furthermore, the trial’s two-stage structure—Phase 1b for dose optimization followed by Phase 2a efficacy assessment—mirrors modern FDA-aligned oncology trial design. These similarities make cross-trial comparisons more credible than they might be for entirely different chemotherapy backbones.

From a strategic standpoint, POLO’s narrower focus on BRCA-mutated patients limited its market size despite regulatory approval. Narmafotinib, by targeting FAK, exploits a tumor biology pathway overexpressed in a far larger proportion of pancreatic cancer patients. This has led some institutional investors to describe Amplia Therapeutics as a “broad-market pancreatic oncology play,” a rare positioning for an ASX-listed biotech.

What could these comparisons mean for Amplia Therapeutics’ future clinical and commercial strategy?

The emerging comparison narrative could help Amplia Therapeutics gain traction among larger oncology drug developers looking for differentiated combination agents. Unlike previous FAK inhibitors that failed as monotherapies, narmafotinib has been developed from the outset as a chemotherapy partner. This strategy is viewed favorably because it mitigates the single-agent efficacy concerns that derailed earlier FAK-targeting programs.

Amplia Therapeutics is also strengthening its U.S. regulatory credibility with its second trial, pairing narmafotinib with FOLFIRINOX under a U.S. FDA Investigational New Drug (IND) application. Designed in line with Project Optimus guidance, which emphasizes dose optimization before large-scale efficacy testing, the new trial may provide data tailored to American treatment protocols. If response rates and survival outcomes remain competitive with MPACT and comparable global studies, Amplia Therapeutics could emerge as a licensing target for mid- to large-cap oncology players looking to expand into pancreatic cancer.

While the ACCENT trial’s survival data are still pending, maintaining or improving upon its current ORR as the trial progresses would further validate its differentiated clinical profile. Any future survival benefit could not only justify regulatory engagement for expedited pathways but also open doors for inclusion in combination therapy guidelines.

Amplia Therapeutics’ strategy places it firmly in the conversation about the next generation of pancreatic cancer treatments. By outperforming MPACT benchmarks in early-phase trials and avoiding the narrow genetic focus of POLO, narmafotinib is carving out a space as a potentially more versatile first-line adjunct.